We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Thallion's Phase II SHIGATEC Trial Proceeds to High Dose Cohort

News   May 18, 2011

 
Thallion's Phase II SHIGATEC Trial Proceeds to High Dose Cohort
 
 
 

RELATED ARTICLES

Tuberculosis Tests are Inadequate, Better Options Identified

News

Rapid blood tests used by the NHS are unable to rule out tuberculosis (TB) and should be replaced with a new, more accurate test, a study has found.

READ MORE

Blindness Prevented in Animal Models of Retinal Degeneration

News

Using a novel patient-specific stem cell-based therapy, blindness was prevented in animal models of geographic atrophy, the advanced 'dry' form of age-related macular degeneration (AMD), which is a leading cause of vision loss among people age 65 and older.

READ MORE

Cellular Protein a Target for Zika Control

News

A cellular protein that interacts with invading viruses appears to help enable the infection process of the Zika virus, according to researchers who suggest this protein could be a key target in developing new therapies to prevent or treat Zika virus infection.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE